Mayne Pharma Group Management

Management criteria checks 2/4

Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 1.58 years. total yearly compensation is A$1.50M, comprised of 44.2% salary and 55.8% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth A$269.31K. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.

Key information

Shawn O’Brien

Chief executive officer

AU$1.5m

Total compensation

CEO salary percentage	44.2%
CEO tenure	1.6yrs
CEO ownership	0.05%
Management average tenure	2.3yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

CEO Compensation Analysis

How has Shawn O’Brien's remuneration changed compared to Mayne Pharma Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Compensation vs Market: Shawn's total compensation ($USD992.05K) is about average for companies of similar size in the Australian market ($USD778.99K).

Compensation vs Earnings: Insufficient data to compare Shawn's compensation with company performance.

CEO

Shawn O’Brien (64 yo)

1.6yrs

Tenure

AU$1,502,156

Compensation

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shawn O’Brien	CEO, MD & Director	1.6yrs	AU$1.50m	0.046% A$ 269.3k
Aaron Gray	Chief Financial Officer	1.8yrs	AU$1.30m	0.016% A$ 96.7k
Kimberly Parker	Executive VP & General Counsel	2.3yrs	no data	no data
Brant Schofield	Executive Vice President of Corporate Development	3.3yrs	AU$1.29m	no data
Erinn Nathaniel	Director of Global Human Resources	1.3yrs	no data	no data
Daniel Moore	Executive Vice President of Commercial	4.7yrs	no data	no data
Frank Casty	Executive VP & Global Chief Medical Officer	1.3yrs	no data	no data
Brenton Walter	Financial Controller	19.8yrs	no data	no data
Laura Loftus	Associate General Counsel & Company Secretary	4.2yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: MYX's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shawn O’Brien	CEO, MD & Director	1.6yrs	AU$1.50m	0.046% A$ 269.3k
Frank Condella	Independent Non-Executive Chairman	6yrs	AU$297.04k	0.081% A$ 479.3k
Bruce Robinson	Independent Non-Executive Director	9.8yrs	AU$166.43k	0.039% A$ 230.8k
Patrick Blake	Independent Non-Executive Director	5.9yrs	AU$212.39k	0.027% A$ 160.6k
Ann Custin	Independent Non-Executive Director	2.2yrs	AU$212.39k	0.026% A$ 155.3k
Kathryn MacFarlane	Independent Non-Executive Director	2.3yrs	AU$212.42k	0.047% A$ 276.3k
Anne Lockwood	Director	less than a year	no data	no data
David Petrie	Independent Non-Executive Director	1.7yrs	AU$137.96k	no data

2.2yrs

Average Tenure

62yo

Average Age

Experienced Board: MYX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Mayne Pharma Group Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Recent updates

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

Analysts lower EPS estimates to -AU$0.094

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?